Next few weeks, I'll be revealing important facts on MHRA, mRNA, and point of care manufacturing

All of it needs stopping in its tracks, now.

What you going to reveal?

1. Advanced Therapies 2023 conference in the UK (London), next week.

2. MHRA Good Distribution Practice (GDP) Symposium

3. POC Manufacturing in UK

See below for the detail:

Advanced Therapies 2023 conference, in London, next week.

This is #1. While the world is fighting for cessation of the SARS-CoV-2 jabs, the pharma industry is pressing ahead with wall-to-wall mRNA jabs

AGENDA: Advanced Therapies 2023 - Check these speaking slots:

March 14, 09:10 Keynote: Tackling manufacturing issues to deliver ATMPs to Patients

Presented by Lonza, the company that manufactures mRNA drug substance for Moderna: Lonza and Moderna Enter New Agreement to Double Drug Substance Production for COVID-19 Vaccine in Visp. Lonza is the world’s largest contract development and manufacturing organisation, (CDMO), but holds no responsibility for ultimate quality.

March 14, 09:30 Panel: Being realistic about the future and commercial sustainability of ATMPs

Peter Marks, Director, Center For Biologics Evaluation And Research (CBER),
U.S. Food and Drug Administration, is a panelist.

Peter Marks is the person responsible for approval of Biological Products (including vaccines) at US FDA—why is he hobnobbing with the guys potentially selling mRNA jabs?

March 14, 10:10 Keynote: Establishing a platform strategy for cell and gene therapy supply chains. Presented by Cryoport Systems CEO.

Cryport is one of many, many companies providing temperature control supply chain services to the ATMP community—it is a provider of logistics services that would make a ton of profit if this went global.

March 14, 11:30 Roundtable 1: Collaboration between patient groups and industry

Ron Jortner, Managing Director, Masthead Biosciences is facilitating. One of many, many companies providing data intelligence and similar services to the ATMP community—if mRNA takes off, Jortner would anticipate making a bundle of cash, although the Masthead website is very thin on detail.

Are you joining up the dots yet?

We need to fight this, as it is the trojan horse for global mRNA jabbing in every shape and flavour.

MHRA Good Distribution Practice (GDP) Symposium

#2 is the MHRA Good Distribution Practice (GDP) Symposium I attended last week.

I’ll be writing an article on it for UK Column, and as a taster, just imagine if Microsoft became the sole provider of technology services to MHRA? What if that involved harvesting patient data, licensing pharmaceutical wholesalers, approving new drugs—not approving others, competitors maybe?

What if surveillance activities to catch criminals (supposedly) thieving medicines was used by MHRAs criminal investigations team, using the latest MS AI App?

Think on and keep tuned to UK Column on this one.

POC Manufacturing in UK

We’ve already touched on this below, where MHRA is allowing manufacture to take place at point of care:

NHS—stop treating us like faceless beings—we are patients, not data for you to harvest

This is a short excerpt: